The mechanism of mesna in protection from cisplatin-induced ovarian damage in female rats

Journal of Gynecologic Oncology

Volumn 24, Issue 2, 2013, Pages 177-185

  Li, Xiaohuan ^a   Yang, Shu ^a   Lv, Xiangyang ^a   Sun, Haimei ^a   Weng, Jing ^a   Liang, Yuanjing ^a   Zhou, Deshan ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Anti M llerian hormone; Cisplatin; Mesna; Ovarian reserve; Oxidative stress

Indexed keywords

CISPLATIN; GLUTATHIONE; LIPID; M 1511; MALONALDEHYDE; MESNA; MUELLERIAN INHIBITING FACTOR; SODIUM CHLORIDE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DAMAGE; CELL STRAIN HEPG2; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; GRANULOSA CELL; HUMAN; HUMAN CELL; LIPID PEROXIDATION; LOW DRUG DOSE; NONHUMAN; OVARIAN RESERVE; OVARY DAMAGE; OVARY DISEASE; OVARY FOLLICLE; OXIDATIVE STRESS; RAT; SPRAGUE DAWLEY RAT;

EID: 84885445461     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2013.24.2.177     Document Type: Article

References (39)

1. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 2000;169:123-131.
2. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998;34:1522-1534.
3. Berger T, Malayeri R, Doppelbauer A, Krajnik G, Huber H, Auff E, et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 1997;33:1393-1399.
4. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 2004;40:2445-2451.
5. Townsend DM, Tew KD, He L, King JB, Hanigan MH. Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity. Biomed Pharmacother 2009;63:79-85.
6. Yucebilgin MS, Terek MC, Ozsaran A, Akercan F, Zekioglu O, Isik E, et al. Effect of chemotherapy on primordial follicular reserve of rat: an animal model of premature ovarian failure and infertility. Aust N Z J Obstet Gynaecol 2004;44: 6-9.
7. Lutchman Singh K, Davies M, Chatterjee R. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update 2005;11:69-89.
8. Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006;98:890-896.
9. Maltaris T, Seufert R, Fischl F, Schaffrath M, Pollow K, Koelbl H, et al. The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J Obstet Gynecol Reprod Biol 2007;130:148-155.
10. Wallace WH, Shalet SM, Crowne EC, Morris-Jones PH, Gattamaneni HR, Price DA. Gonadal dysfunction due to cis-platinum. Med Pediatr Oncol 1989;17:409-413.
11. Stroud JS, Mutch D, Rader J, Powell M, Thaker PH, Grigsby PW. Effects of cancer treatment on ovarian function. Fertil Steril 2009;92:417-427.
12. Nasir J, Walton C, Lindow SW, Masson EA. Spontaneous recovery of chemotherapy-induced primary ovarian failure: implications for management. Clin Endocrinol (Oxf) 1997;46:217-219.
13. Evans DL, Dive C. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and non-proliferating immature thymocytes. Cancer Res 1993;53: 2133-2139.
14. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Perez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007;7:3-18.
15. Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and preven-tion. Hear Res 2007;226:157-167.
16. Choi J, Im GJ, Chang J, Chae SW, Lee SH, Kwon SY, et al. Protective effects of apocynin on cisplatin-induced ototoxicity in an auditory cell line and in zebrafish. J Appl Toxicol 2013;33:125-133.
17. Satoh M, Kashihara N, Fujimoto S, Horike H, Tokura T, Namikoshi T, et al. A novel free radical scavenger, edara-bone, protects against cisplatin-induced acute renal damage in vitro and in vivo. J Pharmacol Exp Ther 2003; 305:1183-1190.
18. Antunes LM, Darin JD, Bianchi Nde L. Effects of the anti-oxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats. Pharmacol Res 2001;43:145-150.
19. Naziroglu M, Karaoglu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 2004;195:221-230.
20. Siu LL, Moore MJ. Use of mesna to prevent ifosfamide-induced urotoxicity. Support Care Cancer 1998;6:144-154.
21. Ypsilantis P, Tentes I, Assimakopoulos SF, Kortsaris A, Scopa CD, Simopoulos C. Mesna ameliorates intestinal mucosa damage after ifosfamide administration in the rabbit at a dose-related manner. J Surg Res 2004;121:84-91.
22. Yeh J, Kim BS, Peresie J. Protection against cisplatin-induced ovarian damage by the antioxidant sodium 2-mercaptoethanesulfonate (mesna) in female rats. Am J Obstet Gynecol 2008;198:463.e1-e7
23. Dale O, Mortensen B, Thommesen L, Hagen B. Cisplatin toxicity in the rat may be influenced by anaesthetic agents. Acta Anaesthesiol Scand 2000;44:770.
24. Oktay K, Schenken RS, Nelson JF. Proliferating cell nuclear antigen marks the initiation of follicular growth in the rat. Biol Reprod 1995;53:295-301.
25. Yeh J, Adashi E. The ovarian life cycle. In: Yen S, Jaffe R, Barbieri R, editors. Reproductive endocrinology. 4th ed. Philadelphia, PA: Saunders WB; 1999. p. 153-190.
26. Stubbs SA, Hardy K, Da Silva-Buttkus P, Stark J, Webber LJ, Flanagan AM, et al. Anti-mullerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries. J Clin Endocrinol Metab 2005;90:5536-5543.
27. Lee MM, Donahoe PK. Mullerian inhibiting substance: a gonadal hormone with multiple functions. Endocr Rev 1993;14:152-164.
28. Gruijters MJ, Visser JA, Durlinger AL, Themmen AP. Anti- Mullerian hormone and its role in ovarian function. Mol Cell Endocrinol 2003;211:85-90.
29. Visser JA, Themmen AP. Anti-Mullerian hormone and folliculogenesis. Mol Cell Endocrinol 2005;234:81-86.
30. Themmen AP. Anti-Mullerian hormone: its role in follicular growth initiation and survival and as an ovarian reserve marker. J Natl Cancer Inst Monogr 2005;34:18-21.
31. Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril 2008;90:395-400.
32. Yeh J, Kim B, Liang YJ, Peresie J. Mullerian inhibiting substance as a novel biomarker of cisplatin-induced ovarian damage. Biochem Biophys Res Commun 2006;348:337-344.
33. Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Mullerian hormone: a new marker for ovarian function. Reproduction 2006;131:1-9.
34. Rosendahl M, Andersen CY, la Cour Freiesleben N, Juul A, Lossl K, Andersen AN. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil Steril 2010;94:156-166.
35. Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009;61:223-242.
36. Kabasakal L, Sehirli AO, Cetinel S, Cikler E, Gedik N, Sener G. Mesna (2-mercaptoethane sulfonate) prevents ischemia/ reperfusion induced renal oxidative damage in rats. Life Sci 2004;75:2329-2340.
37. Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamulu P, Reddy D, et al. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first-and second-generation protecting agents. Semin Oncol 1998;25:584-599.
38. Oprea A, Bazzazi H, Kangarloo B, Wolff JE. The kinetics and mechanisms of the reaction of Mesna with cisplatin, oxiplatin and carboplatin. Anticancer Res 2001;21:1225-1229.
39. Kangarloo SB, Gangopadhyay SB, Syme RM, Wolff JE, Gluck S. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients. Med Oncol 2004;21:9-20.